2.44
+9.42%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About AC Immune
Its shares trade under the ticker ACIU. It has been listed since 23 September 2016. In the fiscal year to 31 December 2025, it reported revenue of CHF 3.6m and a net loss of CHF 70.4m. At that date it held total assets of CHF 154.4m and shareholders' equity of CHF 44.9m.
AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Sept 2016
- Employees
- 122
- Website
- acimmune.com ↗
- Head office
- EPFL INNOVATION PARK, BUILDING B, 1015 LAUSANNE, V8, 00000
- Incorporated in
- V8
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Dr. Douglas WilliamsIndependent Chairman of the BoardCHF 191,000
- Prof. Dr. Andrea PfeiferChief Executive Officer, Co-Founder, Director, since 2003CHF 2.7m
- Prof. Dr. Monika BuetlerIndependent Vice Chairman of the BoardCHF 179,000
- Mr. Christopher RobertsChief Financial Officer
- Mr. Piergiorgio DonatiChief Technical Operations Officer
- Mr. Howard DonovanChief Human Resources Officer
- Dr. Anke PostChief Medical Officer
- Prof. Carl JuneNon-Executive Independent DirectorCHF 124,000
- Dr. Werner LanthalerNon-Executive Independent DirectorCHF 128,000
- Dr. Monica ShawNon-Executive Independent DirectorCHF 138,000
- Dr. Roy TwymanNon-Executive Independent DirectorCHF 134,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 64
- Environment
- 35
- Social
- 88
- Governance
- 70
- Women in the workforce
- 57%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong Research and Development Capabilities: AC Immune SA possesses advanced expertise in neurodegenerative diseases, specifically in the field of Alzheimer's disease.
- Robust Pipeline: The company has a diversified pipeline of potential therapeutics and diagnostics targeting amyloid and tau proteins, which are known to be key drivers of Alzheimer's.
- Strategic Partnerships: AC Immune SA has established collaborations with leading pharmaceutical companies, enabling them to leverage their research capabilities and access additional resources.
Weaknesses
- Dependency on Partnerships: The reliance on partnerships for funding and development support puts AC Immune SA at risk of potential delays or setbacks if collaborations do not meet expectations.
- Limited Product Portfolio: As a biopharmaceutical company focused on neurodegenerative diseases, AC Immune SA's product portfolio is currently concentrated in a specific therapeutic area, limiting diversification.
- Regulatory Challenges: Developing treatments for Alzheimer's disease poses significant regulatory hurdles and uncertainties, which may impact the approval process and timelines.
Opportunities
- Growing Aging Population: The increasing global prevalence of Alzheimer's disease offers significant market potential for AC Immune SA's innovative therapies and diagnostics.
- Emerging Diagnostic Technologies: Advances in diagnostic technologies may present opportunities for AC Immune SA to develop improved diagnostic tools for early detection and monitoring of Alzheimer's.
- Potential for Combination Therapies: Collaboration with other pharmaceutical companies to develop combination therapies may enhance treatment efficacy and open new market opportunities.
Threats
- Intense Competition: AC Immune SA faces competition from large pharmaceutical companies, biotechnology firms, and academic institutions also working on Alzheimer's disease treatments.
- Economic and Financial Uncertainties: Market volatility, economic downturns, or lack of funding could impact AC Immune SA's ability to secure necessary investments for research and development.
- Stringent Regulatory Environment: The stringent regulatory requirements for drug approval may result in extended timelines, increased costs, and potential failure to gain regulatory clearance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.